International Hepatology

Drug-induced liver injury (DILI) is liver damage caused by prescription or over-the-counter chemical medicines, biological products, traditional Chinese medicines, herbal and natural medicines, health products, dietary supplements, or their metabolites, additives, contaminants, and impurities. It is one of the most concerning drug-related diseases globally. At the inaugural 2024 Jinling Liver Disease Conference, Professor Dong Ji from the Fifth Medical Center of the Chinese PLA General Hospital delivered a keynote report on the prognosis of DILI, discussing the histological and biochemical characteristics of chronic DILI and their relationship to its prognosis, and introducing a new non-invasive predictive model for forecasting the prognosis of chronic DILI.

The "Acute-on-Chronic Liver Failure (ACLF) Monthly Review" is a scholarly column produced by the Chinese Acute-on-Chronic Liver Failure Consortium at the invitation of the editorial department of the journal Liver International. Each month, the column focuses on a specific area of ACLF to disseminate knowledge about the concept and significance of ACLF and to help readers stay updated on recent developments in the field. The aim is to benefit both liver disease specialists and researchers interested in field hotspots, as well as frontline clinical practitioners in need of practical knowledge.

Editor's Note:HBV infection remains a significant public health issue worldwide, with about 1.5 million new infections annually. As of 2019, there were 46.5 million children and adolescents globally suffering from…

Non-hepatotropic viruses are significant pathogens in viral hepatitis. With advancements in diagnostic techniques, cases of hepatitis caused by non-hepatotropic viral infections are increasingly recognized in clinical settings. These viruses can manifest solely as hepatitis or in conjunction with other organ disorders. While most infections cause only mild liver damage, viruses such as HHV-6, Coxsackievirus, and adenovirus can lead to acute liver failure in immunocompromised patients, necessitating vigilant monitoring. At the recent 2024 First Jinling Hepatology Conference, Professor Jinghang Xu from Peking University First Hospital delivered a keynote lecture on "Fever with Hepatic Damage," systematically introducing the etiological characteristics, clinical manifestations, and diagnosis of non-hepatotropic viral hepatitis, and shared relevant clinical cases.

Liquid biopsy is a cutting-edge technology that utilizes molecular biomarkers in human body fluids for analysis, thereby obtaining relevant disease information. In the era of precision medicine, liquid biopsy has become an indispensable tool in the field of tumor diagnosis and treatment. It has received extensive attention and research for its applications in early tumor screening, treatment plan selection, disease recurrence monitoring, and biopharmaceuticals. Notably, plasma free DNA fragmentomics, as an emerging technology in the field of liquid biopsy, is increasingly applied in the diagnosis of various cancers.

Primary liver cancer is currently the fourth most common malignant tumor and the second leading cause of cancer death in China, posing a serious threat to the health and well-being of the population. Reducing the burden associated with liver cancer remains a major challenge in the fields of public health and chronic disease prevention in China. Optimizing screening strategies for liver cancer populations is an important ongoing focus and direction. On April 15, 2024, the National Health Commission released the "Primary Liver Cancer Diagnosis and Treatment Guidelines (2024 Edition)," recommending the aMAP, aMAP-2, and aMAP-2 Plus series of liver cancer risk scoring developed by the research team of Professor Jinlin Hou/Professor Rong Fan from Southern Medical University's Southern Hospital for screening and monitoring high-risk liver cancer populations. At the recent 2024 Greater Bay Area Hepatology Summit and the Conference on the Elimination of Viral Hepatitis, Professor Rong Fan delivered an outstanding report titled "Precision Screening for Liver Cancer Patients in China." Our publication has specially invited Professor Rong Fan to provide an in-depth discussion on this hot topic of concern.